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Abstract: Melatonin secretion decreases in Alzheimer´s disease (AD) and this decrease has been postulated as responsi-
ble for the circadian disorganization, decrease in sleep efficiency and impaired cognitive function seen in those patients. 
Half of severely ill AD patients develop chronobiological day-night rhythm disturbances like an agitated behavior during 
the evening hours (so-called “sundowning”). Melatonin replacement has been shown effective to treat sundowning   
and other sleep wake disorders in AD patients. The antioxidant, mitochondrial and antiamyloidogenic effects of melatonin 
indicate its potentiality to interfere with the onset of the disease. This is of particularly importance in mild cognitive  
impairment (MCI), an etiologically heterogeneous syndrome that precedes dementia. The aim of this manuscript was to 
assess published evidence of the efficacy of melatonin to treat AD and MCI patients. PubMed was searched using Entrez 
for articles including clinical trials and published up to 15 January 2010. Search terms were “Alzheimer” and “melatonin”. 
Full publications were obtained and references were checked for additional material where appropriate. Only clinical  
studies with empirical treatment data were reviewed. The analysis of published evidence made it possible to postulate 
melatonin as a useful ad-on therapeutic tool in MCI. In the case of AD, larger randomized controlled trials are necessary 
to yield evidence of effectiveness (i.e. clinical and subjective relevance) before melatonin´s use can be advocated. 
Keywords: Melatonin; Alzheimer´s disease; minimal cognitive impairment; neuropsychological tests; clinical trials.  
INTRODUCTION 
  Oxidative damage has been suggested as the primary 
cause of aging and age-associated neurodegenerative dis-
eases like Alzheimer’s disease (AD). This concept is based 
on the free radical hypothesis of aging as proposed by Har-
man more than 50 years ago [27]. Many recent reviews on 
AD present compelling evidence for a decisive participation 
of severe oxidative stress in the development of neuropa-
thology seen in this disease [1, 5, 6, 10, 19, 57, 65, 71, 73, 
74]. Therefore, numerous compounds with antioxidant prop-
erties have been suggested for treatment of AD and other 
neurodegenerative diseases [24, 42, 61, 62, 78, 81].  
  Among these substances, melatonin emerges as unique 
for several reasons: it is a natural compound synthesized in 
the pineal gland and other body tissues [63], it can be re-
leased by the pineal gland via the pineal recess into the cere-
brospinal fluid (CSF), in much higher concentrations than 
into the circulation [33, 76], and its production decreases 
with age, a fact which has been suggested to a the major pre-
disposing factor in neurodegenerative diseases [52, 71]. This 
review focuses on the therapeutic potential of melatonin in 
AD and in minimal cognitive impairment (MCI), an etiologi-
cally heterogeneous syndrome which progresses to AD at   
an approximate rate of 12 % every year. Since MCI can   
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represent prodromal AD it needs to be adequately diagnosed 
and treated [16].  
MELATONIN AND ALZHEIMER’S DISEASE 
  AD is an age-associated neurodegenerative disease that is 
characterized by a progressive loss of cognitive function, 
loss of memory, and other neurobehavioral manifestations. 
In spite of a large number of studies undertaken, the etiology 
of AD remains largely unknown, although a participation of 
oxidative stress in the development of neuropathology seems 
to be warranted. Many mechanisms have been proposed as 
predisposing for excessive oxidative damage, including the 
genetic background (e.g., expression levels and subforms of 
presenilins and apolipoprotein E), inflammatory processes 
associated with cytokine release, or neurotoxicity by metal 
ions [1, 5, 6, 10, 19, 57, 65, 71, 73, 74]. The deposition of -
amyloid (A) plaques is thought to destabilize neurons by 
mechanisms which require further clarification. Tangles are 
associated with hyperphosphorylation of tau, a microtubule-
associated protein, and of neurofilament H/M subunits, proc-
esses that lead to misfolding and accumulation of altered 
proteins, along with a disruption of microtubules [4, 7, 31, 
32, 55, 60]. 
  However, the simplistic concept that reduces AD lesions 
to oxidative damage has been shown insufficient to explain 
the disease [24, 42, 61, 62, 78, 81]. Classical radical scaven-
gers like vitamins E and C have been used for the treatment 
of AD patients with only limited success. Although some 
studies demonstrated a reduction in lipid peroxidation [30], 
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clinical effects of classical antioxidants [24, 42, 61, 62, 78, 
81]. Moreover, these compounds remained relatively ineffi-
cient in preventing A toxicity and fibrillogenesis [31, 35, 
72].  
  In this regard, melatonin and other structurally related 
indolic compounds, such as indole-3-propionic acid, proved 
to be more potent than classical antioxidants [12, 13, 53, 58]. 
The antifibrillogenic effects of melatonin and its metabolites 
were observed not only in vitro but also in vivo in transgenic 
mouse models [18, 40, 49]. Protection from A toxicity was 
observed, especially at the mitochondrial level. In addition 
melatonin and its related compounds display particular chro-
nobiological properties that make them capable of correcting 
the circadian rhythm disorders seen in AD patients.  
  Many of these actions of melatonin were demonstrated at 
elevated, pharmacological concentrations, but any judgment 
of the physiological relevance of such findings has to con-
sider the relatively high rates of melatonin secretion into the 
CSF, uptake into the brain tissue and, presumably also, the 
metabolism to other protective compounds, such as the N
1-
acetyl-N
2-formyl-5-methoxykynuramine and N
1-acetyl-5-
methoxykynuramine [26], processes which are impaired dur-
ing aging and in neurodegenerative diseases. 
MELATONIN LEVELS IN ALZHEIMER’S DISEASE 
  Several studies have showed that melatonin levels are 
diminished in AD patients compared to age-matched control 
subjects [34, 39, 46, 48, 70, 77]. CSF melatonin levels de-
crease even in preclinical stages when the patients do not 
manifest any cognitive impairment (at Braak stages I-II), 
suggesting that the reduction in melatonin is an early marker 
for the first stages of AD [82, 84].  
  The reduction in nocturnal melatonin levels with the abo-
lition of diurnal melatonin rhythmicity can be the conse-
quence of dysfunction of noradrenergic regulation and deple-
tion of the melatonin precursor serotonin as already seen in 
the earliest preclinical AD stages [82]. Alternatively, 
changes in the pathways of light transmission, from physical 
properties of the dioptric apparatus to a defective retino-
hypothalamic tract or suprachiasmatic nuclei (SCN)-pineal 
connections have been discussed as possible reasons for the 
decline in amplitude of the melatonin rhythm and the corre-
sponding changes in the circadian system [69]. One should, 
however, be aware that light is inhibitory to the pineal, so 
that dysfunction in the transmission of light signals would 
not easily explain a decrease in melatonin. In any case, it is 
clear that the changes in melatonin secretion contribute to the 
frequent symptoms of sleep disruption, nightly restlessness 
and sundowning seen in AD patients. 
  Other reasons may be sought in an altered metabolism of 
AD patients, e.g., in relation to known genetic predisposi-
tions. The presence of apolipoprotein E-4/4, which is asso-
ciated with enhanced A toxicity and more rapid disease 
progression, also leads to considerably stronger declines in 
melatonin in the respective AD subpopulation than in pa-
tients with other apolipoprotein subtypes [34]. From this 
point of view, the relative melatonin deficiency appears as  
a consequence rather than as one of the causes of AD,   
although the loss in melatonin could aggravate the disease. 
Decreased nocturnal melatonin levels were shown to corre-
late with the severity of mental impairment of demented   
patients [36]. 
SLEEP-WAKE AND CIRCADIAN RHYTHM   
ABNORMALITIES IN AD PATIENTS 
  The sleep-wake disturbances in AD patients become 
more marked with progression of the disease. Sleep-wake 
disturbances of elderly AD patients result from changes at 
different levels, such as reductions in the strength of envi-
ronmental synchronizers or their perception, a lack of mental 
and physical activity, age- or disease-induced losses of func-
tionality of the circadian clock. Cross-sectional studies have 
shown that sleep disturbances are associated with increased 
memory and cognitive impairment in AD patients [41].  
  AD patients with disturbed sleep-wake rhythms did not 
only exhibit reduced amounts of melatonin secreted, but also 
a higher degree of irregularities in the pattern of the mela-
tonin rhythm, such as variations in phasing of the peak [46]. 
Therefore, the melatonin rhythm has not only lost signal 
strength in clock resetting, but also reliability as an internal 
synchronizing time cue. Loss or damage of neurons in the 
hypothalamic SCN and other parts of the circadian timing 
system presumably account for the circadian rhythm abnor-
malities seen in demented patients [50, 51, 79], especially as 
the number of neurons in the SCN of AD patients is reduced 
[43]. Clinical findings strongly argue in favor of disruption 
of the circadian timing system in AD, since numerous overt 
rhythms are disturbed, including body temperature and con-
centrations of other hormones such as glucocorticoids [25, 
28]. Circadian alterations, which are detectable at an ad-
vanced stage of AD, also concern phase relationships, such 
as the phase difference between the rest-activity and core 
body temperature cycles, the last one being significantly 
delayed [79].  
  In facing a weakened circadian system the possibility of 
improving rhythmicity in AD patients by well-timed light 
treatment has been entertained [66]. In practical terms, this 
may be important as AD patients were found to be less ex-
posed to environmental light than their age-matched con-
trols, so that dysfunction of the SCN was aggravated by low 
strength of the synchronizing signal light. There is evidence 
that the combined treatment of bright light plus melatonin 
showed the best effects to attenuate cognitive deterioration 
and to improve sleep in old patients [15, 64]. In other words, 
the AD patient is gradually deprived of the photic input and 
even more of the non-photic, darkness-related internal signal 
melatonin. 
  Sundowning, the typical chronobiological phenomenon 
seen in AD, is observed in conjunction with disturbances of 
the sleep-wake cycle. Symptoms appeared in the late after-
noon or early evening and include reduced ability to main-
tain attention to external stimuli, disorganized thinking and 
speech, a variety of motor disturbances including agitation, 
wandering and repetitious physical behaviors and perceptual 
and emotional disturbances [66, 75]. Bright light exposure in 
selected circadian phases markedly alleviated sundowning 
symptoms, such as wandering, agitation and delirium and 
improved sleep wave patterns in AD patients [44, 83]. There-220    Current Neuropharmacology, 2010, Vol. 8, No. 3  Cardinali et al. 
fore, it was logical to test whether melatonin could be an 
effective resynchronizing agent (or chronobiotic) to improve 
this AD patient's condition. 
MELATONIN AS A THERAPEUTIC AGENT FOR 
ALZHEIMER’S DISEASE 
  Melatonin (3 mg p.o. for 21 days) as a sleep-promoting 
agent was first tried in a small non-homogenous group of 
elderly patients with primary insomnia associated with de-
mentia [17]. Seven out of 10 dementia patients having sleep 
disorders treated with melatonin (3 mg p.o. at bed time) 
showed a significant decrease in sundowning and reduced 
variability of sleep onset time. In another study, 14 AD pa-
tients who exhibited irregular sleep-wake cycles, treated with 
6 mg for 4 weeks, showed a significantly reduced percentage 
of nighttime activity as compared to a placebo group [45]. 
The efficacy of 3 mg melatonin/day at bedtime in improving 
the sleep and alleviating sundowning was shown in 11   
elderly AD patients [14] and in 24 patients in other studies 
[37, 38].  
  Long-term administration of melatonin in the dose of 6-9 
mg to 14 AD patients with sleep disorders and sundowning 
agitation for a period of 2-3 years improved sleep quality [8]. 
Sundowning, diagnosed clinically in all patients examined 
was no longer detectable in 12 patients. Another study on 45 
AD patients with sleep disturbances, in which 6 mg of mela-
tonin was given daily for 4 months, confirmed sleep im-
provement and suppression of sundowning [11]. Along with 
this amelioration, which can already be seen as an important 
improvement regarding both the patient and the caregiver, 
the evolution of cognitive alterations in AD patients receiv-
ing melatonin seemed to be halted as compared to AD pa-
tients not receiving melatonin [8, 9]. The major findings of 
those open-label studies were confirmed in a double-blind, 
placebo-controlled study, with regard to sleep-wake rhyth-
micity, cognitive and non-cognitive functions [3].  
  A large multicenter, randomized, placebo-controlled 
clinical trial was undertaken to test melatonin efficacy in AD 
patients [68]. Two dose formulations of oral melatonin were 
applied and 157 subjects with AD and nighttime sleep dis-
turbance were randomly assigned to one of the following 
treatment groups: (i) placebo, (ii) 2.5 mg slow-release mela-
tonin, (iii) 10 mg melatonin, given daily for 2 months. In this 
study melatonin facilitated sleep in a certain number of indi-
viduals, but collectively the increase in nocturnal total sleep 
time and decreased wake after sleep onset, as determined by 
actigraphy were only apparent as trends in the melatonin-
treated groups. On subjective measures, however, caregiver 
ratings of sleep quality showed significant improvement in 
the 2.5 mg sustained-release melatonin group relative to pla-
cebo [68].  
  Large interindividual differences between patients suffer-
ing from a neurodegenerative disease are not uncommon and 
can explain the erratic results seen with melatonin in fully 
developed AD. It should be also taken into account that 
melatonin, though having some sedating and sleep latency-
reducing properties, does not primarily act as a sleeping pill, 
but mainly as a chronobiotic. Since the circadian oscillator 
system is obviously affected in AD patients showing severe 
sleep disturbances, the efficacy of melatonin should be ex-
pected to depend on disease progression. Indeed, melatonin 
failed to improve sleep or agitation in two double-blind ran-
domized placebo-controlled trials in institutionalized patients 
with AD [23, 67]. Thus a major question remains concerning 
melatonin´s efficacy in advanced AD patients. 
 Table  1 summarized the published data concerning mela-
tonin treatment of AD patients. Eight reports (5 open-label 
studies, 2 case reports) (N= 89 patients) supported a possible 
efficacy of melatonin: sleep quality improved and in patients 
with AD sundowning was reduced and cognitive decay 
slowed progression. In 6 double blind, randomized placebo-
controlled trials, a total number of 210 AD patients were 
examined. Sleep was objectively measured by wrist actigra-
phy (N= 5) and additionally neuropsychological assessment 
and sleep quality were subjectively evaluated (N= 6). Sleep 
quality increased and sundowning decreased significantly 
and cognitive performance improved in 4 studies (N= 143) 
whereas there was absence of effects in 2 studies (N= 67). 
  Therefore, the question whether melatonin has a causal 
value in preventing or treating AD, affecting disease pro-
gression of the neuropathology and the driving mechanisms, 
remains unanswered. Double-blind multicenter studies are 
needed to further explore and investigate the potential and 
usefulness of melatonin as an antidementia drug. Its apparent 
usefulness in symptomatic treatment, concerning sleep, sun-
downing, etc., even in a progressed state, further underlines 
the need for such decisive studies. 
MELATONIN AS A THERAPEUTIC AGENT FOR 
MILD COGNITIVE IMPAIRMENT 
  As outlined, melatonin acts at different levels relevant to 
the development and manifestation of AD. The antioxidant, 
mitochondrial and antiamyloidogenic effects may be seen as 
a possibility of interfering with the onset of the disease. 
Therefore, the beginning of treatment is decisive [59]. As 
seen in Table 1 one cannot expect a profound inhibition of 
disease progression once a patient is already in an advanced 
demented state.  
  Mild cognitive impairment (MCI) is an etiologically het-
erogeneous syndrome characterized by cognitive impairment 
shown by objective measures adjusted for age and education 
in advance of dementia. Approximately 12% of MCI convert 
to AD or other dementia disorders every year. Since MCI 
may represent prodromal AD it should be adequately diag-
nosed and treated [16]. Indeed, the degenerative process in 
AD brain starts 20–30 years before the clinical onset of the 
disease. During this phase, plaques and tangles loads in-
crease and at a certain threshold the first symptom appears. 
As already mentioned, CSF melatonin levels decrease even 
in preclinical stages when the patients do not manifest any 
cognitive impairment (at Braak stages I-II), suggesting that 
the reduction in CSF melatonin may be an early trigger and 
marker for AD. Therefore, MCI is the right moment for initi-
ating any melatonin treatment aiming to affect progression of 
the disease. 
  The first report on melatonin treatment of 10 MCI pa-
tients (6 mg/day for 10 days) indicated that besides enhanc-
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Table 1.  Clinical Studies on Melatonin Efficacy in AD 
Design Subjects 
(M, F) 
Treatment Study´s 
Duration 
Measured Results    Reference(s) 
Open-label 
study 
10 (6, 4) 
demented 
patients 
3 mg melatonin 
p.o. daily at bed 
time 
3 weeks  Daily logs of sleep 
and wake quality 
completed by  
caretakers 
Seven out of ten dementia patients  
having sleep disorders treated with  
melatonin showed a significant decrease  
in sundowning and reduced variability  
of sleep onset time 
[17] 
Open-label 
study 
14 (8, 14) 
AD patients 
9 mg melatonin 
p.o. daily at bed 
time 
22 to 35 
months 
Daily logs of sleep 
and wake quality 
completed by  
caretakers.  
Neuropsychological 
assessment. 
At the time of assessment, a significant 
improvement of sleep quality was found. 
Sundowning was not longer detectable  
in 12 patients and persisted, although  
attenuated in 2 patients. Clinically, the 
patients exhibited lack of progression  
of the cognitive and behavioral signs  
of the disease during the time they  
received melatonin.  
[8] 
Case report  Monozygotic 
twins with 
AD of 8 
years dura-
tion 
One of the  
patients was 
treated with  
melatonin 9 mg 
p.o. daily  
at bed time.  
36 
months 
Neuropsychological 
assessment. 
Neuroimaging. 
Sleep and cognitive function severely 
impaired in the twin not receiving  
melatonin as compared to the melatonin-
treated twin. 
[9] 
Open-label, 
placebo-
controlled trial 
14 AD  
patients 
6 mg melatonin 
p.o. daily at bed 
time or placebo 
4 weeks  Daily logs of sleep 
and wake quality 
completed by  
caretakers.  
Actigraphy 
The 7 AD patients receiving melatonin 
showed a significantly reduced  
percentage of nighttime activity  
compared to a placebo group. 
[45] 
Open-label 
study 
11 (3, 8) AD 
patients 
3 mg melatonin 
p.o. daily at bed 
time 
3 weeks  Daily logs of sleep 
and wake quality 
completed by the 
nurses. 
Analysis revealed a significant decrease in 
agitated behaviors in all three shifts, and a 
significant decrease in daytime sleepiness. 
[14] 
Open-label 
study 
45 (19, 26) 
AD patients 
6–9 mg  
melatonin  
p.o. daily  
at bed time 
4 months  Daily logs of sleep 
and wake quality 
completed by  
caretakers.  
Neuropsychological 
assessment. 
Melatonin improved sleep and suppressed 
sundowning, an effect seen regardless of 
the concomitant medication employed to 
treat cognitive or behavioral signs of AD.  
[11] 
Randomized 
double blind 
placebo  
controlled cross 
over study 
25 AD  
patients 
6 mg of slow 
release melatonin 
p.o. or placebo at 
bed time 
7 weeks  Actigraphy  Melatonin had no effect on median total 
time asleep, number of awakenings or 
sleep efficiency. 
[67] 
Double-blind, 
placebo-
controlled 
study 
20 (3, 17) 
AD patients 
Placebo or  
3 mg melatonin 
p.o. daily  
at bed time 
4 weeks  Actigraphy.  
Neuropsychological 
assessment. 
Melatonin significantly prolonged the sleep 
time and decreased activity in the night. 
Cognitive function was improved by  
melatonin. 
[3] 
Randomized, 
placebo-
controlled 
clinical trial 
157 (70, 87) 
AD patients 
2.5-mg slow-
release  
melatonin, or  
10-mg melatonin 
or placebo  
at bed time 
2 months  Actigraphy.  
Caregiver ratings of 
sleep quality 
 Non significant trends for increased  
nocturnal total sleep time and decreased 
wake after sleep onset were observed in the 
melatonin groups relative to placebo. On 
subjective measures, caregiver ratings of 
sleep quality showed improvement in the 
2.5-mg sustained-release melatonin group 
relative to placebo.  
[68] 
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Table 1. Contd…. 
Design Subjects 
(M, F) 
Treatment Study´s 
Duration 
Measured Results    Reference(s) 
Open-label 
study 
7 (4, 3) AD 
patients 
3 mg melatonin 
p.o. daily  
at bed time 
3 weeks  Actigraphy.  
Neuropsychological 
assessment. 
Complete remission of day night rhythm 
disturbances or sundowning was seen in 4 
patients, with partial remission in other 2.  
[37] 
Randomized, 
placebo-
controlled 
study 
17 AD pa-
tients 
3 mg melatonin 
p.o. daily at bed 
time (7 patients). 
Placebo (10 
patients) 
2 weeks  Actigraphy.  
Neuropsychological 
assessment. 
In melatonin-treated group, actigraphic 
nocturnal activity and agitation  
showed significant reductions  
compared to baseline.  
[38] 
Randomized, 
placebo-
controlled 
study 
50 AD pa-
tients 
Morning light 
exposure (2,500 
lux, 1 h) and 5 
mg melatonin 
(n= 16) or  
placebo (n= 17) 
in the evening. 
Control subjects 
(n=17) received 
usual indoor light 
(150-200 lux). 
10 weeks  Nighttime sleep 
variables, day sleep 
time, day activity, 
day:night sleep ratio, 
and rest-activity 
parameters were 
determined using 
actigraphy. 
Light treatment alone did not improve 
nighttime sleep, daytime wake, or  
rest-activity rhythm. Light treatment  
plus melatonin increased daytime wake 
time and activity levels and strengthened 
the rest-activity rhythm.  
[15] 
Case report  68-year-old 
man with 
AD who 
developed 
rapid eye 
movement 
(REM) sleep 
behavior 
disorder 
5 – 10 mg  
melatonin  
p.o. daily  
at bed time. 
20 
months 
Polysomnography  Melatonin was effective to suppress REM 
sleep behavior disorder 
[2] 
Randomized, 
placebo-
controlled 
study 
41 (13, 28) 
AD patients 
Melatonin (8.5 
mg immediate 
release and 1.5 
mg sustained 
release) (N = 24) 
or placebo (N = 
17) administered 
at 10:00 P.M. 
10 days  Actigraphy. 
 
There were no significant effects of  
melatonin, compared with placebo,  
on sleep, circadian rhythms,  
or agitation.  
[23] 
 
ability to remember previously learned items improved along 
with a significant reduction in depressed mood [29]. In an-
other double-blind, placebo-controlled pilot study performed 
in 26 individuals with age-related MCI, the administration of 
1 mg melatonin or placebo at bed time for 4 weeks resulted 
in improvement of sleep and of scores on the California   
Verbal Learning Test-interference subtest [54]. 
  In Argentina melatonin was introduced in 1995 as a reg-
istered medicament for the treatment of sleep disorders in the 
elderly, particularly in those whose endogenous melatonin 
levels are low. Hence, melatonin is often added to the regular 
treatment of old patients who complain of sleep disorders 
and memory disturbances in our environment. This gave us 
the opportunity to carry out a retrospective study of a group 
of 25 MCI patients who received melatonin (3 – 9 mg per 
day) for 9 to 18 months in comparison to a similar group of 
25 MCI patients who did not receive it [20]. Patients treated 
with melatonin showed significantly better performance in 
Mini–Mental State Examination (MMSE) and the cognitive 
subscale of the Alzheimer’s Disease Assessment Scale 
(ADAS-Cog). After application of a neuropsychological 
battery comprising a Mattis´ test, Digit-symbol test, Trail A 
and B tasks and the Rey´s verbal test, better performance 
was found in melatonin-treated patients, except for the Digit-
symbol test which remained unchanged. Abnormally high 
Beck Depression Inventory scores decreased in melatonin 
treated patients, concomitantly with an improvement in 
wakefulness and sleep quality. The results suggested that 
melatonin could be a useful add-on drug for treating MCI in 
a clinic environment [20].  
  A follow up of that study has now been completed and is 
summarized in Figs. (1 and 2). In this expanded retrospective 
analysis a group of 35 MCI patients received melatonin for 9 
to 24 months in comparison to 25 MCI patients who did not Clinical Aspects of Melatonin Intervention in Alzheimer’s Disease  Current Neuropharmacology, 2010, Vol. 8, No. 3    223 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Retrospective analysis of 60 outpatients complaining of MCI symptoms, 35 of which received daily 3 to 9 mg of a fast-release mela-
tonin preparation p.o. at bedtime for 9 to 24 months. Melatonin was given in addition to the individual standard medication prescribed by the 
attending psychiatrist. The other 25 subjects selected received the medication prescribed by the attending psychiatrist which did not include 
melatonin.  Variation of neuropsychological evaluation including are depicted. See text for further details. Shown are the means ± SEM. P 
values denote differences in Z values between final and initial neuropsychological evaluation after a non parametric Mann-Whitney U test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Retrospective analysis of 60 outpatients complaining of MCI symptoms, 35 of which received daily 3 to 9 mg of a fast-release mela-
tonin preparation p.o. at bedtime for 9 to 24 months. For details see Legend to Fig. (1). Shown are the means ± SEM. 224    Current Neuropharmacology, 2010, Vol. 8, No. 3  Cardinali et al. 
Table 2.  Clinical Studies on Melatonin Efficacy in MCI 
Design  Subjects 
(M, F) 
Treatment  Study´s 
Duration 
Measured Results    Reference(s) 
Double-blind, 
placebo-
controlled, 
crossover study 
10 (4, 6) patients  
with MCl 
6 mg melatonin 
p.o. daily at bed 
time 
10 days  Actigraphy.  
Neuropsychological  
assessment. 
Melatonin enhanced the rest-activity 
rhythm and improved sleep quality 
(reduced sleep onset latency and 
number of transitions from sleep to 
wakefulness). Total sleep time  
unaffected. The ability to  
remember previously learned items 
improved along with a significant 
reduction in depressed mood. 
[29] 
Double-blind, 
placebo-
controlled pilot 
study 
26 individuals 
with age-related 
MCI 
1mg melatonin 
p.o. or placebo  
at bed time 
4 weeks  Sleep questionnaire 
and a battery of  
cognitive tests at  
baseline and  
at 4 weeks 
Melatonin administration improved  
reported morning "restedness" and 
sleep latency after nocturnal  
awakening, and also improved scores 
on the California Verbal Learning 
Test-interference subtest. 
[54] 
Open-label, 
retrospective 
study 
50 (13, 37) MCI 
outpatients  
25 had received 
daily 3-9 mg of a 
fast-release  
melatonin  
preparation  
p.o. at bedtime. 
Melatonin was 
given in addition 
to the standard  
medication 
9-18 
months 
Daily logs of sleep and 
wake quality. Initial 
and final neuropsy-
chological assessment. 
Patients treated with melatonin 
showed significantly better  
performance  
in neuropsychological assessment. 
Abnormally high Beck Depression 
Inventory scores decreased in  
melatonin-treated patients,  
concomitantly with an improvement  
in wakefulness and sleep quality.  
[20] 
Randomized, 
double blind, 
placebo-
controlled 
study 
354 individuals 
with age-related 
cognitive decay 
prolonged release 
melatonin  
(Circadin, 2 mg) 
or placebo, 2 h 
before bedtime 
3 weeks  Leeds Sleep  
Evaluation and  
Pittsburgh Sleep  
Questionnaires,  
Clinical Global  
Improvement  
scale score and  
quality of life. 
Melatonin treatment resulted  
in significant and clinically  
meaningful improvements  
in sleep quality, morning  
alertness, sleep onset latency  
and quality of life  
[80] 
Long-term, 
double-blind, 
placebo-
controlled, 2 x 
2 factorial 
randomized 
study 
189 (19, 170) 
individuals with 
age-related 
cognitive decay 
Long-term daily 
treatment with 
whole-day bright 
(1000 lux) or  
dim (300 lux) 
light. Evening 
melatonin (2.5 
mg) or placebo 
administration 
1 to 3.5 
years 
Standardized scales  
for cognitive and 
noncognitive  
symptoms, limitations 
of activities of daily 
living, and adverse 
effects assessed every  
6 months. 
Light attenuated cognitive deteriora-
tion and also ameliorated depressive 
symptoms. Melatonin shortened sleep 
onset latency and increased sleep 
duration but adversely affected scores 
for depression. The combined  
treatment of bright light plus  
melatonin showed the best effects. 
[64] 
Prospective, 
randomized, 
double-blind, 
placebo-
controlled, 
study 
22 (15, 7) indi-
viduals with 
age-related 
cognitive decay  
Participants  
received 2 months 
of melatonin  
(5 mg p.o. /day) 
and 2 months of 
placebo 
2 months  Sleep disorders were 
evaluated with the 
Northside Hospital 
Sleep Medicine  
Institute (NHSMI) 
test. Behavioral disor-
ders were evaluated 
with the Yesavage 
Geriatric Depression 
Scale and Goldberg 
Anxiety Scale. 
Melatonin treatment significantly 
improved sleep quality scores.  
Depression also improved  
significantly after melatonin  
administration.  
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receive it. The diagnostic criteria used for MCI were those of 
Petersen and coworkers [56]. They included amnesic MCI of 
a degenerative nature (insidious onset and gradual progres-
sion), impaired memory, a Clinical Dementia Rating (CDR) 
< 1.0, a Global Deterioration Scale (GDS) < 2.0, with and a 
score of 24 to 30 on the MMSE. All participants were   
informed on the confidentiality of data and on that by no 
means they would be personally identified in case of publica-
tion of the study. 
  Thirty-five patients in the sample selected had received 
daily 3 to 9 mg of a fast-release melatonin preparation 
(Melatol
®, Elisium S.A., Buenos Aires, Argentina) given p.o. 
at bedtime. The patients were indicated to take melatonin 30 
min before the expected time of sleep every day. Melatonin 
was given in addition to the individual standard medication 
prescribed by the attending psychiatrist. The other 25 sub-
jects selected had received the medication prescribed by the 
attending psychiatrist which did not include melatonin. Pa-
tients with a minimum of 9 and a maximum of 24 months of 
treatment were included. The neuropsychological evaluation 
included the MMSE, ADAS-Cog and a neuropsychological 
battery consisting of the Mattis´ test, Digit-symbol test, Trail 
A and B tasks and the Rey´s verbal test. A 21-item Beck 
Depression Inventory and a global assessment of wakeful-
ness and sleep quality were also completed for each subject 
[20].  
  Scores for the MMSE range from 0 to 30, with higher 
scores indicating better function. Scores for the ADAS-Cog 
range from 0 to 70, with higher scores indicating poorer 
function. Mattis´ scores range from 0 to 144 with higher 
scores indicating better function. Digit-symbol, Trail A and 
B tasks should be normally completed in less than 10, 120 
and 150 seconds, respectively. Normal scores for Rey´s ver-
bal test should be > 85 while those for Beck inventory 
should be < 20. Scores for wakefulness and sleep quality 
scales range from 0 to 10, with higher scores indicating bet-
ter function. In all cases the  variation of parameter was 
computed. Statistical analysis of results was performed by 
non-parametric Mann-Whitney U tests.  
  As shown in Figs. (1 and 2), melatonin-treated MCI pa-
tients performed better in the MMSE and ADAS-Cog tests, 
as well in the full neuropsychological battery applied except 
for the Digit-symbol test. The abnormally high Beck Depres-
sion Inventory score decreased in melatonin-treated MCI 
patients, concomitantly with an improvement in wakefulness 
and sleep quality. The results confirm and extend the obser-
vations supporting a role of melatonin as a useful add-on 
drug for treating MCI in a clinic environment.  
  A randomized controlled trial on the effect of bright light 
and melatonin on cognitive and noncognitive function in 
elderly residents of group care facilities was recently pub-
lished [64]. The authors concluded that light has a benefit in 
improving some cognitive and noncognitive symptoms of 
MCI which was amplified by the conjoint administration of 
melatonin. Melatonin alone had an adverse effect on mood. 
In other two similar studies, one of them using the prolonged 
release preparation of melatonin (Circadin
TM) recently   
approved by the European Medicines Agency, melatonin 
resulted in significant and clinically meaningful improve-
ments in sleep quality, morning alertness, sleep onset latency 
and quality of life in old patients with mild cognitive   
impairment [22, 80]. In these studies melatonin treatment al 
improved mood. 
 Table  2 shows a summary of published data concerning 
melatonin treatment of MCI patients. Five double blind,   
randomized placebo-controlled trials and 1 open-label   
retrospective study (N= 651) all agree in indicating that 
treatment with daily evening melatonin improves sleep   
quality and cognitive performance in MCI. 
CONCLUSION 
  The mechanisms that account for therapeutic effects of 
melatonin in AD and MCI patients remain to be elucidated. 
Since the symptomatic actions become relatively rapidly 
apparent, they should be initially of a chronobiological na-
ture. Melatonin treatment has been shown to promote mainly 
non-rapid eye movement (REM) sleep in the elderly [47] and 
is found beneficial in AD by supporting restorative phases of 
sleep. The chronobiological aspect is underlined by a study 
on golden hamsters, in which melatonin was able to protect 
against the circadian changes produced by A25-35 microin-
jection into the SCN [21]. Regardless of the mechanistic 
details, all pertinent data unanimously direct to a sleep-
promoting effect of melatonin in AD and MCI patients, as 
generally in elderly insomniacs.  
  Although there is evidence to postulate melatonin as a 
useful ad-on therapeutic tool in MCI, larger double-blind 
multicenter studies are urgently needed to further explore 
and investigate the potential and usefulness of melatonin as 
an antidementia drug. Its apparent usefulness in symptomatic 
treatment, concerning sleep, sundowning or cognitive im-
pairment, even in a progressed state, further underlines the 
need for such decisive studies. 
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